Pfizer Inc. (PFE) is
not the most exciting stock to own, since it is not likely to produce huge
growth rates. But this does not necessarily mean it is a bad investment. Far
from it, particularly for income investors. Pfizer offers investors a steady
stream of dividends and a high yield, backed by a strong and highly profitable
business model.
Pfizer is a good example of a slow-and-steady dividend
stock. It has a long history of steady growth, and dividends. The company has
been in operation for more than 100 years. Combined with its 3%+ dividend
yield, these two qualities earn Pfizer a place on our list of “blue-chip”
stocks. You can see the full list of blue chip stocks here.
Pfizer has a dividend yield of approximately 3.9%, which is
more than double the average stock in the S&P 500. And, thanks to a robust
product pipeline, it has the financial strength to raise its dividend each
year. The stock also has a modest valuation right now, which could make it
attractive for value and income investors.
Earnings Overview:
Pfizer is one of the largest U.S. pharmaceutical companies,
with a market capitalization of $210 billion. It researches and manufactures
drugs for a variety of therapeutic areas. Pfizer operates two reporting
segments:
Innovative Health (60% of revenue)
Essential Health (40% of revenue)
Common therapeutic areas for Pfizer are internal medicine,
oncology, immunology, inflammation, and rare diseases. Pfizer’s global
portfolio is based mostly on biopharmaceuticals, but it also includes vaccines.
On May 1st, Pfizer released first-quarter financial results.
Overall, the results were strong. Revenue of $12.91 billion missed expectations
by $240 million but rose 1% from the same quarter a year ago.
In case you interested of stock analysis of other bloggers, click on link below: